How effective is Alpelisib in treating breast cancer?

Alpelisib - Piqray, as an innovative PI3Kα inhibitor, is one of the important breakthrough drugs in the field of targeted treatment of breast cancer in recent years. It is specifically indicated for the treatment of patients with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced or metastatic breast cancer who have PIK3CA gene mutations. Such mutations will lead to the continuous activation of cell signaling pathways, thereby promoting the growth and drug resistance of cancer cells. Apelvis precisely inhibits the PI3Kα pathway, cuts off the proliferation signals of cancer cells, and controls tumor progression from the root.

In terms of therapeutic effect, multiple overseas studies and real-world application data show that Apelvis can significantly delay disease progression, especially in patients who have developed resistance after receiving endocrine therapy, showing new therapeutic value. Compared with traditional chemotherapy or single hormone therapy, Apelvis can target the mutation pathway more precisely, thereby improving the overall response rate and disease control rate. It is worth noting that apelvis is not used alone, but in combination with Fulvestrant. The two work synergistically to further inhibit cell proliferation signals on the basis of hormone receptor positivity, thereby prolonging progression-free survival.

Based on clinical experience, the efficacy of Apelvis is often closely related to the patient's genetic characteristics. Testing methods approved by the FDA can screen out patients with PIK3CA mutations, and this group of people will benefit most. Since PIK3CA mutations account for approximately 30%-40% of breast cancer patients, this means that Apelvis has the potential to change the treatment path for a considerable number of breast cancer patients. Currently, in European and American countries, Apelvis has become the standard second-line or third-line endocrine combination treatment option, bringing new hope to countless relapsed or drug-resistant patients.

Reference materials:https://www.piqray.com/